INTRODUCTION

C
lostridium difficileis an obligate anaerobic grampositive bacillus that is part of the intestinal microbiota, both in man and in other animals 1 . It was first isolated in 1935 and so named because of the difficulties encountered in achieving its culture. In 1978, it was identified as the main agent causing pseudomembranous colitis, the sigmoid and rectum being the main sites of Bacterial spores remain in the environment for extended To choose the correct treatment, it is important to classify the severity of the disease (Table 1) 9 . Most studies and guidelines establish the therapeutic regimens based on the clinical picture, severity, risk of recurrence and complications. The two most commonly used drugs are metronidazole and vancomycin. Table 2 illustrates the scheme currently used 10 . In Brazil, there are few studies on C. difficile infection, generally attributed to the difficulty of access to the tests for detecting the bacteria, mainly in the public health system, thus being an underdiagnosed disease in our country 11 .
In a recent guideline of the European Society Two independent researchers reviewed the texts in their entirety and selected the ones that had the most evidence on the subject, excluding those that
were not in agreement with the objective and/or that touched on the proposed subject. We also included the bibliographic references of the selected articles.
RESULTS AND DISCUSSION
The imbalance of the intestinal microbiota, In 2010, members of several specialized medical societies formed a working group with the aim of developing a consensus on treatment is that all the forms studied were more efficient than the treatment with antibiotics 15 . The enema pathway presented a high rate of resolution of symptoms. However, in most cases it was necessary to repeat the procedure several times until obtaining the clinicalimprovement.
Infection severity was a decisive factor for the outcome.
More severe cases were more refractory to treatment. No adverse effects were observed, the application is simple and, according to some reports, can be carried out by the patient in the home environment 29 .
The nasogastric route is effective and safe for patients with contraindications to the colonoscopic route and it is well accepted, even though patients with advanced age are somewhat disgusted. The biggest concern is the vomiting and aspiration of the infused contents 12 . In the only Brazilian study on FMT, ten patients underwent the treatment with oral enteroscopy with 90% healing rate.
It is believed that the enteroscopic route is also an option to be considered for patients with contraindications to other forms of application. Due to the need for sedation, the physical and moral discomfort of nasogastric infusion of fecal material is avoided 
CONCLUSIONS
Fecal microbiota transplantation (FMT) is a proven technique, with low costs when compared to conventional treatment, and with few adverse effects.
Refractory and severe cases are the main indications of FMT. All forms of application had a high cure rate, and the colonoscopic route was the most used.
In view of the severity of Clostridium difficile infection, it is not surprising that patients consider FMT as an alternative treatment. Education and patient involvement in the decision-making process are crucial factors for acceptance of the technique. It is perceptible through research that the physician has great influence in the choice of treatment to be performed and, if prescribed, there is a high probability of acceptance.
The lack of indication rests on the prejudice towards the procedure.
The lack of regulation and institutional protocols leads to insecurity and is a barrier that needs to be overcome. The adequate use of this technique will only be feasible through the disclosure of its effectiveness, knowledge of the administration routes and acceptance of health professionals.
A infecção por Clostridium difficile é uma complicação comum após a disbiose intestinal ocasionada pelo uso abusivo de antibióticos.
Apresenta elevada importância médica devido às altas taxas de recorrência e morbidade. O transplante de microbiota fecal é uma alternativa eficaz para o tratamento da infecção recorrente e refratária pelo C. difficile e consiste na introdução da microbiota intestinal de um doador saudável em um paciente portador desta infecção. O mecanismo fisiológico exato pelo qual o transplante de microbiota fecal altera a microbiota intestinal não está tão bem estabelecido, mas é evidente que restaura a diversidade e a estrutura da microbiota promovendo aumento da resistência à colonização pelo C. difficile. Diversas vias de administração do transplante estão sendo estudadas e utilizadas de acordo com as vantagens apresentadas. Todas as formas de aplicação apresentaram elevada taxa de cura, sendo a via colonoscópica a mais utilizada. Não foram documentados complicações e efeitos adversos relevantes, e seu custo benefício em relação ao tratamento convencional se mostrou vantajoso. Apesar da sua eficácia é pouco utilizado como terapia inicial, sendo necessários mais estudos para firmar essa terapêutica como primeira opção no caso de infecção por Clostridium difficile refratária e recorrente.
Descritores: Transplante de Microbiota Fecal. Clostridium difficile. Enterocolite Pseudomembranosa. Antibacterianos.
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